Wolfgang Tolle - Chairman of the Board
VisionCare, Inc.

Mr. Tolle is an accomplished and successful executive, entrepreneur and business advisor with over 25 years of experience in the ophthalmology industry, the technology sector and business advisory services. He was most recently President & COO of PostCreator, a Washington-area technology business. From 2011 to 2014, Mr. Tolle was General Manager of Alcon Benelux (Belgium, Netherlands, and Luxemburg), a division of Novartis, where he was responsible for all Alcon product lines including surgical, pharmaceutical, and contact lenses. In this capacity, Mr. Tolle guided the integration of Alcon Benelux into Novartis AG, the Swiss multinational that completed its acquisition of Alcon in 2011. Prior to that, he was CEO of WaveLight Inc. and WaveLight AG/GmbH, a publicly traded German producer of premium refractive ophthalmic lasers acquired by Alcon Inc. Earlier, he was President and CEO of LaunchDreams LLC, a Northern Virginia firm that provides advisory services to U.S. and international technology and related businesses.

Mr. Tolle holds “Diplom der Informatik mit Nebenfach Betriebswirtschaftslehre”, “Sehr gut”, from the University of Dortmund, Germany in August 1986 (German equivalent to an MS degree, magna cum laude, in Computer Science in conjunction with a simultaneous BS in Business Management). Over time, Mr. Tolle has served on numerous corporate, non-profit and civic entities. In addition to being on VisionCare's Board, he currently serves on the Board of Nathan Associates Inc.

Blake Michaels
President and Chief Executive Officer VisionCare, Inc

Mr. Michaels is an accomplished and successful sales and marketing executive with over 30 years of experience in the ophthalmic device industry. He was most recently Vice President of Sales and Customer Service Operations at VisionCare. Prior to that, Blake held the position of Director of Key Accounts for Alcon Laboratories (Novartis), where he was on the original launch team commercializing the LenSx femtosecond laser for cataract surgery. He has also been a Regional Director of Sales for Alcon in the refractive division, coming over in the acquisition of WaveLight in late 2007, where he was VP, Sales and Marketing for the US subsidiary. Prior to WaveLight/Alcon, Mr. Michaels was the Director of Marketing for Bausch and Lomb’s US cataract business, where he led the global launch of the SofPort AO advanced optic IOL and the EasyLoad injector system. Mr. Michaels was also part of the original launch team for the first scanning spot, tracking excimer designed by Autonomous Technologies. Before that, Mr. Michaels was a long time employee of Storz Instrument Company, where he served in many capacities in the commercial organization.

Mr. Michaels received his BA in Biology from Colgate University and his MBA in Marketing Management from the City University of New York/Baruch College.

Thierry Clidiere

Mr. Clidiere brings more than forty years of executive experience in marketing, sales and acquisition management within the pharmaceutical and medical device industry. Launching his career at Pfizer, Inc., Mr. Clidiere held various roles in the areas of sales, marketing, operations and business development in several of their international offices. In 1983, he joined Alcon Laboratories, where he spent the next 28 years in executive management positions including General Manager & President of Alcon Spain, Area President of Alcon Latin America, Area President of Alcon Europe, Middle East & Africa and, until 2011, Vice President Strategic and Commercial Integration Alcon/Novartis.

Steve DeNelsky
Life Sciences Alternative Funding

Mr. DeNelsky has over twenty years of healthcare investment experience across all sectors including medical devices and diagnostics. Prior to founding LSAF in 2013, Mr. DeNelsky worked for twelve years at various hedge funds as a healthcare analyst and portfolio manager. Mr. DeNelsky managed Sapphire Capital a healthcare only hedge fund that returned mid-high teens returns from 2005-2007 and attracted over $230 million in capital. Mr. DeNelsky served as lead director of Amicas (NASDAQ: AMCS) a healthcare technology company from 2001-2010. Prior to his direct investment experience, Mr. DeNelsky was a Senior Equity Analyst at CS First Boston, Deutsche Bank and Furman Selz covering a variety of healthcare services companies. Before coming to Wall Street, Mr. DeNelsky worked in the healthcare industry for a healthcare consulting, mergers and acquisitions and valuation firm based in Washington D.C.

Rich Gumer
Life Sciences Alternative Funding

Mr. Gumer has over 25 years of experience in the healthcare industry, focused primarily on medical devices and pharmaceuticals. Together with Steve DeNelsky, Mr. Gumer founded LSAF in early 2013 to provide structured growth capital to the Medical Device and Diagnostics industries. Previously, he was the senior healthcare analyst at Avenue Capital, a global hedge fund with $20 billion of assets under management, responsible for all healthcare investing. Prior to Avenue, Mr. Gumer was the Global Head of Healthcare Private Equity investing for GE Capital. He also previously headed the Healthcare Investment Banking units ABN Amro and was involved in more than $10 billion of equity, debt and M&A transactions. Mr. Gumer was previously on the Boards of several private companies, including Steri-Oss (sold to Nobel Biocare) and IVPcare (sold to Oncology Therapeutics Network). He has an AB in Biochemistry from Brown University and an MBA in Finance from University of California, Berkeley.

David Kho
Life Sciences Alternative Funding

Mr. Kho has over eight years of experience in the venture and debt spaces, with experience across all healthcare sectors, including medical devices and diagnostics. Prior to joining LSAF, he worked for over six years at Square 1 Bank, most recently as a Vice President in the Life Sciences practice in Boston. Before joining Square 1, Mr. Kho was a performance analyst at Hatteras Investment Partners, a boutique investment firm. He has a BS in Business Administration from the University of North Carolina at Chapel Hill.

The AMD Market Opportunity

According to estimates based on National Eye Institute statistics, advanced age-related macular degeneration (AMD) in one or both eyes with associated vision loss affects approximately 2 million people in the U.S.